Back to discover
Drug

Dexmedetomidine

Established medicine
ResearchActive indication expansion
Also known as Dexased, Dexdomitor, Dexmedesed, Dexmedvet+12 more

Dexased, Dexdomitor, Dexmedesed, Dexmedvet, Igalmi, Precedex, Sedexodine, Sileo, Dexmed-etomidine, Dexmedetomidin, Dexmedetomidina, Dextmedetomidine, dexemedetomidine, (+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole, Dexmedetomidine Hydrochloride, Dexmedetomidinum.

10
Research papers
25
Active clinical trials
5
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Dexmedetomidine
Aliases & brands
DexasedDexdomitorDexmedesedDexmedvetIgalmiPrecedexSedexodineSileoDexmed-etomidineDexmedetomidinDexmedetomidinaDextmedetomidinedexemedetomidine(+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazoleDexmedetomidine HydrochlorideDexmedetomidinum
RxNorm CUI
48937
ChEMBL ID
CHEMBL778
ATC codes
N05CM18
UNII
67VB76HONO
Regulatory jurisdictions
fda

Regulatory timeline

5 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval on record (generic/biosimilar)
2019-01-18
Latest approval
2019-01-18
Authorities
FDA
Total events
5
fdaU.S. Food and Drug Administration· 5 events
2026-10-22Label change
Label change: DEXMEDETOMIDINE (ANDA204843)
Evidence ↗
2026-10-22Label change
Label change: DEXMEDETOMIDINE (ANDA204843)
Evidence ↗
2026-10-22Label change
Label change: DEXMEDETOMIDINE (ANDA204843)
Evidence ↗

Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).

Clinical trials

188 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
188
registered trials across all phases
LATEST COMPLETION 2026
25
Active studies
20
Recruiting
159
Late-stage (III+)
112
Completed
51
Discontinued
PHASE DISTRIBUTIONn = 188
Early Phase 19Phase 15Phase 1 / 23Phase 212Phase 2 / 37Phase 319Phase 473Phase N / A60

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

10 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
2005–2025
Most influential
Recent papers
Major research themes8
Hypnotics and Sedatives3Dexmedetomidine2Analgesics1Autistic Disorder1Delirium1Evidence-Based Medicine1Mental Disorders1Monitoring, Intraoperative1
Journals, researchers & institutions
Top journals
  • Paediatric anaesthesia2
  • Anesthesiology1
  • Clinical drug investigation1
  • Hospital pediatrics1
  • Intensive care medicine1
  • Pain1
Leading researchers
  • Berkenbosch JW2
  • Ben-Menachem E1
  • Ben-Zeev B1
  • Berkenstadt H1
  • Borao L1
  • Bourguignon N1
  • Chanques G1
  • Constantin JM1
Leading institutions
free-text, unnormalised
  • Baylor College of Medicine1
  • Boston Children's Hospital1
  • Centre Hospitalier d'Aurillac1
  • Centre Hospitalier d'Avignon1
  • Centre Hospitalier de Montluçon1
  • Centre Hospitalier de Moulins Yzeure1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.